ATE474579T1 - Thiadiazol-derivate zur behandlung von neurodegenerativen erkrankungen - Google Patents

Thiadiazol-derivate zur behandlung von neurodegenerativen erkrankungen

Info

Publication number
ATE474579T1
ATE474579T1 AT07711455T AT07711455T ATE474579T1 AT E474579 T1 ATE474579 T1 AT E474579T1 AT 07711455 T AT07711455 T AT 07711455T AT 07711455 T AT07711455 T AT 07711455T AT E474579 T1 ATE474579 T1 AT E474579T1
Authority
AT
Austria
Prior art keywords
disease
treatment
thiadiazole derivatives
neurodegenerative diseases
syndrome
Prior art date
Application number
AT07711455T
Other languages
English (en)
Inventor
Gerard Griffioen
Kristel Marie Edith Coupet
Hein Roger Duhamel
Stefaan Wera
Ellen Gomme
Damme Nele Van
Der Auwera Ingrid Van
Marleen Lox
Dooren Tom Van
Tine Decruy
Original Assignee
Remynd Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remynd Nv filed Critical Remynd Nv
Application granted granted Critical
Publication of ATE474579T1 publication Critical patent/ATE474579T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07711455T 2006-02-07 2007-02-07 Thiadiazol-derivate zur behandlung von neurodegenerativen erkrankungen ATE474579T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0602335.2A GB0602335D0 (en) 2006-02-07 2006-02-07 Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
PCT/EP2007/001022 WO2007090617A2 (en) 2006-02-07 2007-02-07 Thiadiazole derivatives for the treatment of neuro degenerative diseases

Publications (1)

Publication Number Publication Date
ATE474579T1 true ATE474579T1 (de) 2010-08-15

Family

ID=36101115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07711455T ATE474579T1 (de) 2006-02-07 2007-02-07 Thiadiazol-derivate zur behandlung von neurodegenerativen erkrankungen

Country Status (15)

Country Link
EP (1) EP1981504B1 (de)
JP (1) JP5283511B2 (de)
CN (1) CN101378757B (de)
AT (1) ATE474579T1 (de)
AU (1) AU2007213954B2 (de)
BR (1) BRPI0707700B8 (de)
CA (1) CA2641453C (de)
DE (1) DE602007007890D1 (de)
DK (1) DK1981504T3 (de)
EA (1) EA018067B1 (de)
ES (1) ES2348999T3 (de)
GB (1) GB0602335D0 (de)
PL (1) PL1981504T3 (de)
PT (1) PT1981504E (de)
WO (1) WO2007090617A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2137162B1 (de) * 2007-03-15 2018-08-01 Novartis AG Organische verbindungen und anwendungen davon
US20090325964A1 (en) * 2008-05-23 2009-12-31 Wyeth Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
CN102066347B (zh) * 2008-06-27 2016-06-08 拜耳知识产权有限责任公司 噻二唑氧苯基脒及其作为杀菌剂的应用
CN102414412B (zh) 2009-05-04 2014-12-31 巴斯夫公司 用于稀燃汽油机的改进的twc的稀烃转化
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
ES2540956T3 (es) * 2011-07-01 2015-07-15 Remynd Nv Derivados de 1,2,4-tiadiazol-5-ilpiperazina útiles en el tratamiento de enfermedades neurodegenerativas
AU2012296804B2 (en) * 2011-08-17 2017-04-20 Remynd Nv Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
WO2015092420A1 (en) 2013-12-20 2015-06-25 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
EP3119774A1 (de) * 2014-03-17 2017-01-25 reMynd NV Oxadiazolverbindungen
MX2023001758A (es) * 2020-08-11 2023-04-11 Univ Michigan State Potenciadores de proteasoma y usos de los mismos.
WO2025104092A1 (en) 2023-11-13 2025-05-22 Remynd N.V. Modulators of septin 6 for use in the prevention and/or treatment of neurodegenerative disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060472A (en) 1998-04-06 2000-05-09 Apotex Inc. Thiadiazole compounds useful as inhibitors of H+ /K+ atpase
WO2002083863A2 (en) * 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
MXPA06001845A (es) * 2003-08-21 2006-05-04 Pfizer Prod Inc Compuestos para el tratamiento de trastornos neurodegenerativos.
US7232820B2 (en) * 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine

Also Published As

Publication number Publication date
ES2348999T3 (es) 2010-12-21
BRPI0707700B1 (pt) 2020-08-04
BRPI0707700B8 (pt) 2022-12-20
DK1981504T3 (da) 2010-11-08
PT1981504E (pt) 2010-10-13
CN101378757B (zh) 2012-08-01
CA2641453C (en) 2013-07-30
HK1122989A1 (en) 2009-06-05
CN101378757A (zh) 2009-03-04
AU2007213954A1 (en) 2007-08-16
PL1981504T3 (pl) 2010-12-31
CA2641453A1 (en) 2007-08-16
WO2007090617A3 (en) 2008-02-28
JP2009526000A (ja) 2009-07-16
GB0602335D0 (en) 2006-03-15
WO2007090617A2 (en) 2007-08-16
EA018067B1 (ru) 2013-05-30
DE602007007890D1 (de) 2010-09-02
AU2007213954B2 (en) 2011-09-22
EP1981504B1 (de) 2010-07-21
JP5283511B2 (ja) 2013-09-04
EA200870233A1 (ru) 2009-02-27
EP1981504A2 (de) 2008-10-22
BRPI0707700A2 (pt) 2011-05-10

Similar Documents

Publication Publication Date Title
DE602007007890D1 (de) Thiadiazol-derivate zur behandlung von neurodegenerativen erkrankungen
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
MY162640A (en) Thioninium compounds and their use
MY150558A (en) A pharmaceutical composition comprising rebamipide
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
ATE495164T1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
SG10201912182UA (en) Improved modalities for the treatment of degenerative diseases of the retina
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
WO2019175260A3 (en) Modified oligonucleotides for use in treatment of tauopathies
TN2010000155A1 (en) Organic compounds
MY149492A (en) Immunoglobulins directed against nogo
WO2009019295A3 (en) Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases
NL1033562A1 (nl) Tetrahydropyridoazepine-8-onen en verwante verbindingen voor de behandeling van schizofrenie.
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
MX340564B (es) Isoformas de neurregulina solubles activas modificadas post-traduccionalmente.
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
WO2022204362A3 (en) Compositions and methods for treating a neurodegenerative or developmental disorder
WO2008050133A3 (en) Inhibition of beta-amyloid aggregation
ATE549923T1 (de) Makrozyklische spiropiperidin-beta-sekretase- hemmer zur behandlung von morbus alzheimer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1981504

Country of ref document: EP